Literature DB >> 1606085

Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study.

G Meloni1, U Raucci, R M Pinto, A Spalice, M Vignetti, P Iannetti.   

Abstract

A neurological and electroencephalographic (EEG) prospective study was performed in 34 leukemic patients receiving busulfan (BU) plus cyclophosphamide (CY) before bone marrow autologous transplant. During BU treatment and briefly thereafter, all patients were given anticonvulsant prophylaxis with phenobarbital. Neurological evaluations were performed daily and EEGs, recorded one week before and soon after the end of the BU regimen, were re-evaluated two months later. Basal EEGs were normal in 23 of the 34 patients, focal abnormalities were detected in 9 cases, and generalized epileptic discharges were present in one (one subject was not studied). EEGs performed at the end of BU administration showed generalized spike/polyspike-and-wave discharges in 21 of the 34 patients, with associated myoclonic epilepsy in 10 subjects appearing on the 3rd or 4th day of treatment. Focal abnormalities were present in 6 patients and constant EEG normality in 7. It is known that myoclonic epilepsy can be induced by drugs. Oral administration of high-dose BU is followed by a high-dose cerebrospinal fluid concentration of the drug. Therefore, myoclonic epilepsy and/or paroxysmal epileptiform EEG discharges may be observed in leukemic patients undergoing high-dose BU therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606085     DOI: 10.1093/oxfordjournals.annonc.a058131

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

Review 1.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

2.  Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Authors:  Eucario Leon-Rodriguez; Monica M Rivera-Franco
Journal:  Int J Hematol       Date:  2016-10-08       Impact factor: 2.490

3.  Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients.

Authors:  H I Tahsildar; B F Remler; R J Creger; B W Cooper; S M Snodgrass; R W Tarr; H M Lazarus
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 4.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

Review 6.  A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Melissa Gabriel; Bianca A W Hoeben; Hilde Hylland Uhlving; Olga Zajac-Spychala; Anita Lawitschka; Dorine Bresters; Marianne Ifversen
Journal:  Front Pediatr       Date:  2021-12-23       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.